hsa-mir-181c: Hsa-mir-181c is a microRNA that is potentially involved in a positive feedback loop to activate the calcineurin/NFAT pathway by silencing the negative regulator of the pathway, CSNK1A1 [PMC5831902]. It has been found to have a significant positive correlation with kidney chromophobe (KICH), liver hepatocellular carcinoma (LIHC), and cholangiocarcinoma (CHOL), and a negative correlation with breast invasive carcinoma (BRCA) and lung squamous cell carcinoma (LUSC) [PMC7074167]. Hsa-mir-181c is part of the miR-181 family, which also includes miR-181a and miR-181b [PMC5831902]. It has been shown to be downregulated in hepatocellular carcinoma (HCC), lung cancer, and breast cancer [PMC7074167][PMC8914318][PMC5503581]. In addition, hsa-mir-181c has been found to be differentially expressed in tamoxifen-resistant and tamoxifen-sensitive breast cancer cell lines [PMC5820911]. Furthermore, hsa-mir-181c expression has been associated with response to platinum-based chemotherapy in cancer patients [PMC6359307]. Hsa-mir-181c has also been shown to exhibit differential expression in periapical and pulp tissues [PMC9987318]. Overall, hsa-mir-181c appears to play a role in various biological processes and may have potential as a biomarker or therapeutic target in cancer.